Arquel

Quick links to important sections

Arquel

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Arquel

Property Description
Active Ingredient Meclofenamic Acid (or Meclofenamate Sodium)
Form Capsule, Oral Suspension, Oral Granule
Pharmacological Class Nonsteroidal Anti-Inflammatory Drug (NSAID)
Common Use Pain relief and inflammation reduction
Origin Synthetic Organic Compound (Fenamate)

What Type of Medicine is Arquel (Meclofenamic Acid)?

Arquel is the name of a medicinal entity whose active component is the Fenamate compound, Meclofenamic Acid, formally classified as a Nonsteroidal Anti-Inflammatory Drug (NSAID). This classification corresponds to the Anatomical Therapeutic Chemical (ATC) code M01AG04. The drug is a synthetic organic compound, chemically identified as an Anthranilic Acid Derivative. The Fenamate sub-class, including Meclofenamic Acid, is used for its properties in managing inflammatory pain, establishing its primary role as an analgesic and anti-inflammatory agent.

Composition and Pharmaceutical Form

The medicine is supplied as a single-active-ingredient product intended for Oral consumption. The core component is Meclofenamic Acid, which is commonly processed and administered as its salt, Meclofenamate Sodium, to ensure optimal stability and solubility. This medication is available in several dosage forms for ingestion, most commonly the Capsule and Oral Suspension. The fenamate group is characterized by an effective absorption profile when taken orally. A distinctive feature of this Fenamate is its historical approval and usage in certain equine applications, differentiating its scope beyond typical human NSAIDs.

General Therapeutic Purpose

The general therapeutic purpose of this agent is the management of pain and the reduction of inflammatory symptoms throughout the body. Arquel functions as an anti-inflammatory agent and analgesic agent by inhibiting the synthesis of prostaglandins, which are the key endogenous chemical messengers responsible for triggering pain, swelling, and fever. This mechanism makes the drug effective for providing relief from both mild to moderate pain and the physical manifestation of tissue inflammation.

What side effects are possible with Arquel?

Possible Side Effects and Safety Information

The information below is based strictly on the officially documented safety profile of Arquel (Meclofenamate Sodium) as defined by government regulatory authorities.

Serious Safety Risks

Official regulatory documents emphasize the potential for serious, sometimes fatal, cardiovascular and gastrointestinal risks. The serious adverse effects include an increased risk of cardiovascular thrombotic events (such as myocardial infarction and stroke) and severe gastrointestinal events (including bleeding, ulceration, and perforation of the stomach or intestines). These risks may increase with the duration of use and higher doses.

Other documented serious reactions include severe hepatic (liver) reactions, serious skin reactions (e.g., Stevens-Johnson Syndrome, Toxic Epidermal Necrolysis), and anaphylactic reactions.

Frequency-Classified Adverse Reactions

Adverse reactions are formally classified by frequency in regulatory labeling. The most frequently reported effects (categorized as Very Common ge 10%) are typically related to the gastrointestinal system, such as diarrhea and nausea. Common ( ge 1% to < 10%) effects include vomiting, abdominal pain, and flatulence. Less commonly reported effects include conditions like tinnitus and hearing loss.

System-Organ Class Examples of Documented Effects
Gastrointestinal Disorders Diarrhea, Nausea, Vomiting, Ulceration
Cardiovascular Disorders Thrombotic events, Hypertension, Edema
Skin and Subcutaneous Tissue Disorders Rash, Severe skin reactions

Safety-Related Restrictions

Regulatory documents include specific restrictions on use. Arquel is contraindicated (should not be used) immediately before or after Coronary Artery Bypass Graft (CABG) surgery. It is also restricted in patients with a history of allergic-type reactions (e.g., asthma, urticaria) after taking aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs). The drug is also not recommended during late pregnancy (from 30 weeks onward) due to documented risks to the fetus.

Overdose and Emergency Response

Overdose and When to Seek Help

The regulatory profile for Arquel (Meclofenamic Acid) outlines the potential manifestations and the required emergency response following acute overexposure. Documented presentations of overdose may include gastrointestinal symptoms such as nausea, vomiting, and epigastric pain, alongside central nervous system effects like drowsiness, confusion, lethargy, and tinnitus.

Severe Manifestations and Risks System Potential Complications
Gastrointestinal Bleeding, Ulceration, or Perforation
Neurological Convulsions, Seizures, or Coma
Renal Acute Kidney Injury or Anuria

Severe or life-threatening outcomes are possible, including acute renal failure and cardiovascular thrombotic events. Individuals in the elderly population face a greater risk for serious gastrointestinal adverse events, which is noted for overdose management. Since no specific antidote is known for Arquel overexposure, regulatory guidance mandates immediate emergency help-seeking.

Mandatory Emergency Actions Individuals must seek medical attention right away and contact a Poison Control Center upon suspicion of overdose. Emergency medical care is required for the onset of symptoms such as chest pain, shortness of breath, weakness on one side of the body, or slurred speech. Management is officially described as symptomatic and supportive, potentially involving gastric lavage or activated charcoal procedures.

Therapeutic Uses of Arquel

What Arquel Treats: Main Uses and Benefits

The primary therapeutic domain of Arquel (risedronate sodium) is applied across domains where additional symptomatic support is needed related to conditions where functional stability becomes affected. Arquel belongs to a class of medications called bisphosphonates and is considered relevant in conditions characterized by periods of heightened symptoms associated with acute or episodic changes.

Indications for this medication include the treatment and prevention of osteoporosis in postmenopausal women, the treatment to increase bone mass in men with osteoporosis, and the treatment and prevention of glucocorticoid-induced osteoporosis in men and women. It is also indicated for the treatment of Paget’s disease of bone.

Arquel is commonly used to help with symptoms that interfere with daily comfort. The clinical context for its use often involves scenarios where symptoms may intensify temporarily, and supportive symptom management is appropriate. Through its intended therapeutic application, Arquel may assist with maintaining functional stability and contributes to easing the overall symptom load during episodes of heightened discomfort.


Quick Fact: Supports general well-being during symptomatic phases


Eligibility and Restrictions for Use

Eligibility and Contraindications for Arquel (Meclofenamic Acid)

Arquel (Meclofenamic Acid) is restricted to specific patient populations as defined by official regulatory labeling. The medicine is strictly contraindicated for individuals with a known hypersensitivity to meclofenamic acid or any history of allergic reactions, such as asthma or hives, triggered by aspirin or other Nonsteroidal Anti-Inflammatory Drugs (NSAIDs).

Absolute prohibition also applies to patients with severe organ system impairment, including active gastrointestinal (GI) ulceration, severe heart failure, or severe renal failure. Use is also contraindicated for the treatment of pain in the setting of coronary artery bypass graft (CABG) surgery.

Population-Specific Rules

Regarding age and development, the safety and efficacy have not been established in children younger than 14 years of age. Older adults are advised to use the lowest effective dose for the shortest duration possible due to an increased risk of serious GI events.

For pregnant women, Arquel is contraindicated starting at 30 weeks gestation due to the risk of harm to the fetus. Use is also generally not recommended for women who are breastfeeding or attempting to conceive. Patients with pre-existing mild to moderate heart, liver, or renal impairment require cautious use and clinical monitoring.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documentation structures the interaction profile of Meclofenamic Acid (Arquel) around significant pharmacokinetic and pharmacodynamic risks, emphasizing combinations that may lead to additive toxicity or reduced drug clearance.

Interaction Scope and Restrictions

Category Documented Entities/Statements
Medicinal product categories Non-Aspirin Systemic NSAIDs, Oral Anticoagulants, Diuretics, ACE Inhibitors, ARBs, SSRIs, Cyclosporine.
Specific interacting medicines Aspirin (low-dose), Digoxin, Lithium, Methotrexate.
Contraindicated Combination Use for peri-operative pain in Coronary Artery Bypass Graft (CABG) Surgery is formally contraindicated.

Co-administration with systemic non-aspirin NSAIDs should be avoided due to the documented risk of increased adverse effects, particularly serious gastrointestinal events. The drug is reported to cause a synergistic increase in the risk of gastrointestinal bleeding when combined with oral anticoagulants like Warfarin or with SSRIs.

Pharmacokinetic and Renal Clearance Effects

Meclofenamic Acid is officially documented to interfere with renal elimination, which leads to elevated plasma exposure of several co-administered drugs. Co-administration with Lithium results in increased plasma concentrations and reduced renal clearance of Lithium. Similarly, the regulatory label notes a risk of increased Methotrexate plasma concentration due to reduced renal elimination.

Antihypertensive and Absorption Notes

Interactions are documented to diminish the effectiveness of antihypertensive agents such as ACE Inhibitors, ARBs, and Diuretics by inhibiting renal prostaglandin synthesis. Food intake officially reduces the rate of absorption of Meclofenamic Acid, though the overall absorbed amount is unchanged. Geriatric patients are noted to be at greater risk for interaction-related nephrotoxicity.

Mechanism of Action

How Arquel Works: The Mechanism of Action

The mechanism of Arquel (Meclofenamic Acid) involves targeted intervention across the biochemical pathways influencing eicosanoid signals.


Enzymatic Inhibition of Eicosanoid Synthesis

Arquel primarily acts as a competitive inhibitor of the Cyclooxygenase (COX) enzymes, specifically targeting both the constitutive COX-1 and the inducible COX-2 forms. This direct blockade halts the initial molecular step that converts Arachidonic Acid into key chemical messengers called Prostaglandins. This action limits the production of the mediators that sensitize peripheral nerves and initiate fluid accumulation, resulting in attenuation of peripheral signaling and modulation of localized tissue responses.


Dual Pathway Modulation and Receptor Interference

The mechanism extends beyond COX inhibition, including evidence of interference with the 5-Lipoxygenase (5-LOX) pathway, which limits the creation of Leukotrienes. Additionally, the drug acts as an antagonist at certain Prostaglandin Receptors. This dual-pathway approach and receptor blockade create a broad intervention profile, which results in modulation of the inflammatory signaling network.


Central and Peripheral Nociceptive Modulation

The drug's mechanism is active in both peripheral tissues and the Central Nervous System (CNS). Centrally, the inhibition of COX activity suppresses the synthesis of Prostaglandin E2 (PGE2) in the hypothalamus, which directly influences the hypothalamic thermoregulatory set point. This simultaneous central and peripheral action on key physiological regulators contributes to the systemic modulation of nociceptive and thermoregulatory signaling.

Dosage and Administration Information

How Arquel is Used: Official Dosing and Administration

Arquel (Meclofenamic Acid/Meclofenamate Sodium) is administered following specific parameters regarding usage patterns, routes, and dosing.

Official Route and Dosage Forms

Arquel is administered via the Oral route. It is primarily supplied as Capsules in strengths of 50 mg and 100 mg of Meclofenamate Sodium.

Standard Labeled Dosing Regimens

The total daily dose must not exceed 400 mg for any indication. Regimens are administered in divided doses:

Indication Standard Regimen Frequency and Duration
Mild to Moderate Pain 50 mg to 100 mg per dose. Every 4 to 6 hours as needed. Use should be for the shortest duration possible.
Arthritis (Rheumatoid/Osteo) 200 mg to 400 mg total daily dose. Administered in three or four equal doses per day.
Dysmenorrhea 100 mg per dose. Three times a day (t.i.d.), typically for up to 6 days.

Administration Conditions and Adjustments

To ensure proper administration and reduce potential gastrointestinal complaints, the medicine may be taken with meals or with milk.

The overarching principle for use is to employ the lowest effective dosage for the shortest duration consistent with patient needs. For older adults, a reduced initial dosage and careful monitoring are specifically recommended. The drug is generally not recommended for patients with advanced renal disease.

Recent Clinical Evidence

Research evidence / Overview of studies for Arquel (Meclofenamic Acid)


Evidence for Use in Chronic Inflammatory Conditions (Osteoarthritis and Rheumatoid Arthritis)

Short- to intermediate-term controlled clinical trials were conducted, in which the active ingredient, Meclofenamic Acid, was evaluated in conditions characterized by fluctuating or episodic manifestations, such as chronic arthritis. Research explored the agent's use for examining patterns in reported symptoms in both osteoarthritis (OA) and rheumatoid arthritis (RA) in adult populations. Studies were conducted during periods of increased symptom activity and often used comparative designs against placebo or other compounds.

For both conditions, research monitored outcomes related to physical discomfort, including patient-reported measures of pain on walking or night pain in OA, and the severity and duration of morning stiffness in RA. Findings describe patterns observed in the studies related to these symptom axes over the study period. However, comparative evidence is lacking against the full range of newer therapeutic options, and long-term effects are not fully established by controlled evidence.


Research Evidence for Pain and Symptom Management in Women's Health

Research examined the agent in trials assessing short-term or episodic symptom patterns associated with women's health. The evidence includes randomized, double-blind crossover trials exploring its application for both primary dysmenorrhea (menstrual pain) and for evaluating outcomes related to heavy menstrual blood loss (MBL). Follow-up durations were limited to monitoring across a few menstrual cycles. Data are still emerging for its use in patients with underlying gynecological conditions, as these groups were often excluded from the core trials.


Studies on Acute, Short-Term Pain Relief

Arquel was evaluated in studies focusing on acute pain. This research explored short-term symptom changes, primarily using single-dose, placebo-controlled trials conducted on adult and adolescent populations experiencing mild to moderate acute pain following events such as dental or minor surgical procedures. The studies monitored patient-reported outcomes describing perceived discomfort and tracked objective measures such as the time-course of perceived pain change. Data for certain groups remain insufficient, particularly for acute pain monitoring in populations with complex, co-existing health issues.

Key Studies & References

  1. Pharmacological and clinical profile of meclofenamate sodium
  2. Meclofenamate sodium in the treatment of osteoarthritis of the knee. A double-blind trial
  3. WHO Collaborating Centre for Drug Statistics Methodology, Anatomical Therapeutic Chemical (ATC) Classification Index (Meclofenamic acid: M01AG04)

Frequently Asked Questions (FAQ)

Common questions about Arquel (FAQ)


Q: What are the most common side effects of Arquel reported by patients?

A: Regulatory safety summaries categorize side effects by how frequently they are reported. According to official product information, the most common side effects (Very Common, reported in ge 10% of people) are typically related to the digestive system, such as diarrhea and nausea.


Q: Can Arquel cause weight gain or weight loss?

A: Official product information documents the potential for fluid retention, also known as edema, as a documented adverse effect. Fluid retention can lead to an increase in body weight. Changes in fluid retention are typically reviewed by a healthcare professional.


Q: Is it normal to feel tired when first starting Arquel?

A: Official regulatory documents do not list fatigue or significant tiredness as common side effects. However, nonspecific drowsiness and dizziness are documented adverse reactions in the official prescribing information. Individuals are generally advised to monitor how they feel when starting any new medication.


Q: Why do doctors prescribe Arquel for the condition?

A: Arquel (Meclofenamate Sodium) is prescribed because it belongs to a class of medicines called Nonsteroidal Anti-Inflammatory Drugs (NSAIDs). The drug's therapeutic purpose, as officially stated, is to help manage mild to moderate pain and to reduce physical symptoms related to inflammation in the body.


Q: What is the maximum amount of time someone can take Arquel?

A: The official drug administration guidelines emphasize that Arquel should be used for the shortest duration possible. It is used for both acute (short-term) pain and for chronic conditions like arthritis. The appropriate length of use is determined by a prescribing healthcare professional, as research evidence on long-term effects is not fully established.


Q: Is it normal to not feel the drug working right away?

A: Arquel is typically prescribed with dosing intervals every 4 to 6 hours, which suggests that the onset of effects may begin relatively quickly. However, the time it takes for a patient to perceive relief can vary based on the condition being treated and individual body factors.


Q: Does the time of day matter when taking Arquel?

A: Official instructions do not require Arquel to be taken at a specific time of day (morning or night). However, the prescribing information states that it may be taken with meals or with milk. This is generally recommended to help manage the potential for gastrointestinal discomfort.


Q: Is Arquel available over the counter?

A: No. According to regulatory labeling and classifications in the United States and other official jurisdictions, Arquel (Meclofenamate Sodium) is designated as a prescription-only medication and is not available over the counter.


Q: Is Arquel considered a 'new' drug?

A: No. The active ingredient, Meclofenamic Acid, has been regulated and used in medicine for many decades. It is chemically classified as a first-generation NSAID, indicating it is not considered a new medication within its drug class.


Q: Does Arquel interact with common foods or drinks?

A: Regulatory documents note that taking the drug with food may reduce the rate of absorption but does not change the total amount absorbed by the body. Official warnings also specifically emphasize avoiding alcohol while taking this medication due to an increased risk of serious gastrointestinal bleeding.


Q: What kind of studies support the use of Arquel?

A: The regulatory approval of Arquel was based on evidence from controlled clinical trials. These studies focused on the drug’s use for short- to intermediate-term relief in adults with specific conditions, including inflammatory disorders and acute pain. Evidence includes randomized, double-blind designs.


Q: How long does Arquel stay in your system?

A: Based on official pharmacokinetic data, the active component has a relatively short elimination half-life, typically ranging from less than one hour to just over five hours in healthy adults. This half-life refers to the time it takes for half of the drug to be eliminated from the body.


Q: Can Arquel be taken by children or teenagers?

A: Official regulatory labels clearly state that the safety and effectiveness of Arquel have not been established in children younger than 14 years of age. Use in patients 14 years and older is detailed in the official prescribing instructions.


Q: What should I do if I feel worse after starting Arquel?

A: Official patient counseling information emphasizes the importance of seeking prompt medical attention if symptoms of a serious adverse event, such as an allergic reaction, chest pain, or bleeding, are experienced. Regulatory guidance prioritizes monitoring for any serious or unexpected reactions.


Q: Is Arquel addictive or habit-forming?

A: Arquel (Meclofenamate Sodium) is classified as a Nonsteroidal Anti-Inflammatory Drug (NSAID). It is not scheduled as a controlled substance by regulatory bodies and is therefore not generally considered to be addictive or habit-forming.


Q: Do studies show Arquel is effective for all patients?

A: Clinical trials evaluate the drug's effects across groups of patients. Regulatory summaries acknowledge that response to the medication can vary from person to person. Official information notes that the drug's effectiveness is not fully established for all populations or for all potential long-term uses.


Q: Is Arquel a maintenance drug or a short-term treatment?

A: Arquel is officially indicated for the treatment of acute (short-term) mild to moderate pain. It is also approved for the chronic management of symptoms associated with rheumatoid arthritis and osteoarthritis, making it suitable for both short and longer-term uses, depending on the condition.


Q: Can Arquel be taken with other medicines for the same condition?

A: Official regulatory warnings advise against combining Arquel with other systemic non-aspirin NSAIDs. This combination carries a documented risk of increasing the likelihood of serious gastrointestinal adverse events, such as bleeding or ulcers.


Q: Why do some people say Arquel did not work for them?

A: Research and regulatory documents recognize that there can be variability in patient response to any medication. Factors like individual variations in how the body handles the medicine and the specific characteristics of the patient's condition can influence the perceived effect.


Q: Is Arquel associated with any specific organ damage?

A: Official warnings document serious risks associated with potential adverse effects on several organ systems. This includes the gastrointestinal tract (bleeding/ulceration), the cardiovascular system (thrombotic events), and potential issues with the liver (hepatic reactions) and kidneys (renal failure).


Q: Can men and women take Arquel equally?

A: Arquel is indicated for general use in both male and female patients for its primary purpose of managing pain and inflammation. The drug is also officially indicated for a women's health use, such as the management of dysmenorrhea (menstrual pain).


Q: Is Arquel used in other countries besides the US?

A: Yes. The active ingredient in Arquel (Meclofenamic Acid) is recognized and listed in the World Health Organization's (WHO) global classification system. This indicates that it is utilized and recognized by health systems in multiple countries outside of the United States.


Q: Is Arquel a biologic drug?

A: No. The official documents describe Arquel (Meclofenamic Acid) as a synthetic organic compound. It is chemically classified as a Nonsteroidal Anti-Inflammatory Drug (NSAID) and is not categorized as a biologic agent.

How should Arquel be stored and disposed of?

How to Store and Dispose of Arquel

The storage and disposal instructions for Arquel (Meclofenamic Acid) are defined by regulatory labeling to maintain product integrity and safety.


Storage Requirements

Condition Requirement
Temperature Store at controlled room temperature, typically 20 C to 25 C (68 F to 77 F), with permitted excursions [up to 30 C].
Protection Keep the container tightly closed and away from excess heat, moisture, and direct light. The product must not be exposed to freezing temperatures.
Child Safety Store the medication out of the sight and reach of children; safety caps must be locked and the medicine secured in an area that is up and away.

Disposal Instructions

Unused or expired Arquel should be disposed of via an official drug take-back program at authorized collection sites when available. If a take-back program is not accessible, the product may be mixed with an undesirable substance, sealed in a container, and placed in the household trash. It must not be flushed down the toilet or poured down a drain unless specifically instructed by the product label.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Arquel found in:

A-Z Index: